Trial
NCT03399578
Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Oxford
Collaborators
—
Condition
MERS (Middle East Respiratory Syndrome)
Intervention
ChAdOx1 MERS
Why stopped
The scientific questions proposed remain relevant, but will now be addressed in a larger phase II immunogenicity trial of the ChAdOx1 MERS vaccine given at 2 doses.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-20